Protocol Ledger

Academic / Cooperative Group · Consolidated Sponsor Hub

UCSF: Clinical Trials & FDA Approval Profile

UCSF (San Francisco, CA) sponsors 109 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 50 active protocols (36 recruiting now), 36 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)21.1%
Median Closed Enrollment vs National (145 pts)27 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for UCSF
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)109
Active Pipeline (Recruiting Now)50 (36)
Completed vs Stopped Early36 / 23 (21.1%)
Median Closed Actual Enrollment27 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With UCSF
Hospital Research SiteLocationShared Protocols
UCSF Medical Center and Helen Diller Cancer CenterSan Francisco, CA75
Huntsman Cancer Institute at University of UtahSalt Lake City, UT6
Duke University Medical CenterDurham, NC6

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by UCSF
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06861244Embryonal Tumor With Multilayered RosettesPhase IIRECRUITING
NCT07226453Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) EpendymomaPhase IIRECRUITING
NCT05009992Combination Therapy for the Treatment of Diffuse Midline GliomasPhase IIRECRUITING
NCT07110246Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade GliomasPhase IIRECRUITING

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for UCSF Health across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the UCSF Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI